In another study, the combination therapy of gatipotuzumab with the EGFR-targeting antibody tomuzotuximab showed some anti-tumor activity in heavily pretreated EGFR-positive non-small cell lung cancer (NSCLC) patients and colorectal cancer (CRC) [24]. This evidence concerns the gene EGFR and neoplasm.